Memantinhydrochlorid Beta (Memantine Hydrochloride)

Memantine Hydrochloride works by blocking the NMDA receptor’s ion channel in a non‑competitive manner. This reduces excessive calcium entry into neurons caused by overstimulation with glutamate, limiting excitotoxic damage and supporting neuronal communication that underlies cognition.

The specific dose of Memantinhydrochlorid Beta is determined by the prescribing clinician based on the patient’s age, disease severity, renal function, and other individual factors. Healthcare providers follow approved dosing guidelines and adjust as needed during treatment.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While those agents increase acetylcholine levels, memantine targets glutamatergic excitotoxicity via NMDA receptor blockade. Clinical practice often combines both classes for complementary mechanisms, but individual response and tolerability guide selection.

Store the product at room temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Memantinhydrochlorid Beta is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless the formulation specifically permits it.

Serious risks include the potential for seizures, severe allergic reactions such as anaphylaxis, cardiac arrhythmias, and the emergence of suicidal thoughts or worsening depression. Patients should be monitored closely for any new or worsening neurological or psychiatric symptoms.

Memantinhydrochlorid Beta is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, unless a healthcare professional determines that benefits outweigh risks.